Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Bajaj Healthcare surges after secures SEC recommendation for Cenobamate tablets
Bajaj Healthcare soared 12.98% to Rs 345 after the company said that Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO) has recommended for grant of approval for manufacturing and marketing of Cenobamate Tablets.
Bajaj Healthcare secures SEC recommendation for Cenobamate tablets
Bajaj Healthcare announced that Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO) has recommended for grant of approval for manufacturing and marketing of Cenobamate Tablets.
Central Drugs Laboratories find 46 drug samples not of standard quality for May
Health officials revealed that in May 2026, 46 drug samples tested by Central Drugs Laboratories and 113 by State Drugs Testing Laboratories were found to be of substandard quality. Additionally, one spurious drug, manufactured by an unauthorized entity using another company's brand, was identified in Assam and is under investigation. These findings highlight ongoing efforts to ensure drug safety and remove substandard products from circulation.
Laurus Labs, Biocon, Ather Energy, Lenskart among probable MSCI India Standard Index inclusion candidates, says JM Financial
JM Financial anticipates significant shifts in the MSCI India Standard Index. Laurus Labs and Biocon are flagged as high-probability additions from the Small Cap Index, while Ather Energy and SAIL are medium-probability candidates. SBI Card faces a high probability of exclusion. These potential changes could lead to substantial passive fund inflows into India, estimated around $3.2 billion, impacting institutional investors.
August MSCI Rejig Could Trigger Over Rs 30,000 Crore Inflows Into India; Laurus Labs, Biocon Lead Race
Among the likely beneficiaries, Laurus Labs and Biocon have been assigned a high probability of moving from the MSCI India Small Cap Index to the MSCI India Standard Index.
Stock Alert: Sun Pharma, GRSE, GE Power, Goodluck India, Zaggle Prepaid, Texmaco Rail - Business Standard
Stock Alert: Sun Pharma, GRSE, GE Power, Goodluck India, Zaggle Prepaid, Texmaco RailBusiness Standard
Stock Alert: SBI, Aurionpro Solutions, MedPlus Health, Honasa Consumer, Bharat Wire Ropes, IOL Chemicals & Pharma - Business Standard
Stock Alert: SBI, Aurionpro Solutions, MedPlus Health, Honasa Consumer, Bharat Wire Ropes, IOL Chemicals & PharmaBusiness Standard
Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns
The Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approval for semaglutide injections. A diabetes patient raised concerns about the drug's delivery system, alleging it deviates from global standards and poses health risks. The court has directed the CDSCO to consider the patient's representation within two months.
Vande Bharat Trains Abroad? India Eyes Export Of Train Sets For Africa, Latin America: Report
India is preparing to take its indigenously developed Vande Bharat Express trains to the overseas markets, with plans to develop a standard-gauge version of the semi-high-speed train.
Stock Alert: ITC, Honasa Consumer, Aurobindo Pharma, Nykaa, Welspun Corp - Business Standard
Stock Alert: ITC, Honasa Consumer, Aurobindo Pharma, Nykaa, Welspun CorpBusiness Standard
Stock Alert: Apollo Hospitals, Lenskart Solutions, Metro Brands, Whirlpool of India - Business Standard
Stock Alert: Apollo Hospitals, Lenskart Solutions, Metro Brands, Whirlpool of IndiaBusiness Standard
Aurobindo Pharma arm gets CDSCO marketing nod for Bevqolva
Aurobindo Pharma said the Central Drugs Standard Control Organization (CDSCO) has granted marketing authorization under Form CT 23 for the bevacizumab biosimilar for metastatic carcinoma of the colon or rectum.